Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03262545
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chendu, Sichuan, China
Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03261791
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- DongMa
- Target Recruit Count
- 40
- Registration Number
- NCT03255811
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 66
- Registration Number
- NCT03254654
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03251443
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Peking University
- Target Recruit Count
- 11
- Registration Number
- NCT03251417
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
Phase I Study of the Combination of Apatinib and POF
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03244774
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
A Study To Test The Effect Of Apatinib On P450 Enzymes
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03245307
- Locations
- 🇨🇳
Chinese Medical University First Hospital, Shenyang, Liaoning, China
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT03243838
- Locations
- 🇨🇳
Guangdong general hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong General Hospital, Guangzhou, China
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03243643
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chendu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.